Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation | Zendy

Winnie Ip | Zendy; Waseem Qasim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation

Author(s) -

Winnie Ip,

Waseem Qasim

Publication year - 2013

Publication title -

advances in hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.371

H-Index - 31

eISSN - 1687-9112

pISSN - 1687-9104

DOI - 10.1155/2013/176418

Subject(s) - medicine , hematopoietic stem cell transplantation , stem cell , haematopoiesis , transplantation , disease , immunology , incidence (geometry) , adoptive cell transfer , intensive care medicine , t cell , immune system , genetics , physics , optics , biology

Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research